Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Targeting CD36 in Macrophages and Endothelial Cells for the Treatment of Atherosclerosis
AmorChem Canada flag Canada
Abstract ID:
CD36 is now known to play a major role in foam cell formation in both atherosclerotic mouse models and in humans. Selective lead azapeptides that impact atherosclerotic lesion formation/progression via targeting of CD36 are being developed....
Contact John Clement
Participants
You
Email me a copy of this message

Atherosclerosis is the main underlying cause of ischemic heart disease and related cardiovascular complications including acute myocardial infarction and stroke. In view of the failure of statins to benefit all patients, exhaustive research efforts have been directed at different research avenues, in acknowledgement of the improved basic knowledge regarding lipoprotein metabolism, macrophage function and the inflammatory condition associated with atherosclerosis.

In this regard, the role of macrophage scavenger receptors in clearing oxidatively modified LDL has been thoroughly investigated. Ultimately, CD36 has been shown to play a pivotal role in atherosclerosis development and the aim of this program is to identify an azapeptide lead for development that impact atherosclerotic lesion formation/progression via targeting of CD36.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Out-licensing or collaboration
FEATURED
Last Updated Aug 2016
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION